Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation

Journal of Vascular Surgery

Volumn 49, Issue 1, 2009, Pages 211-213

  Ali, Faisal R ^a   Roberts, Lara N ^a   Mistry, Hiren ^a   Patel, Raj K ^a   Edmondson, Robert A ^a   Arya, Roopen ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYUREA; JANUS KINASE 2; POLITEF; WARFARIN;

ADD ON THERAPY; ADULT; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BELOW KNEE AMPUTATION; BLOOD CELL COUNT; BONE MARROW BIOPSY; BYPASS SURGERY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ECHOGRAPHY; FOOT PAIN; GENE MUTATION; GRAFT OCCLUSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG REVASCULARIZATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POPLITEAL ARTERY; PRIORITY JOURNAL; RECURRENT DISEASE; SAPHENOUS VEIN; SUPERFICIAL FEMORAL ARTERY; THROMBECTOMY; THROMBOCYTOSIS; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; RADIOGRAPHY, INTERVENTIONAL; RECURRENCE; THROMBOEMBOLISM; TREATMENT FAILURE; VASCULAR SURGICAL PROCEDURES;

EID: 58449101222     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.07.007     Document Type: Article

References (13)

1. Elliott M.A., and Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128 (2005) 275-290
2. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the World Health Organisation diagnostic criteria for polycythaemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
3. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
4. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
5. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
6. Ingram W., Lea N.C., Cervera J., Germing U., Fenaux P., Cassinat B., et al. The JAK2 V617F mutation identified a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukaemia 20 (2006) 1319-1321
7. Levine R.L., Loriaux M., Huntly B.J.P., Loh M.L., Beran M., Stoffregen E., et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukaemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 106 (2005) 3377-3379
8. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C., Marsden J., et al. Definition of the subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
9. Cheung B., Radia D., Pantelidis P., Yadegarfar G., and Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. B J Haematol 132 (2006) 244-245
10. Finazzi G., Rambaldi A., Guerini V., Carobbo A., and Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92 (2007) 135-136
11. Hexner E. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol 14 (2007) 450-454
12. Patel R.K., Lea N.C., Westwood N.B., Milojkovic D., Thanigaikumar M., Yallop D., et al. Prevalence of activating JAK2 kinase mutation V617F in the Budd Chiari syndrome. Gastroenterology 130 (2006) 2031-2038
13. Remacha A.F., Estivill C., Sarda M.P., Mateo J., Souto J.C., Canels C., et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 109 (2007) 339-342